| 1 |
33984481 | Pseudo Heparin Resistance After Pulmonary Endarterectomy: Role of Thrombus Production of Factor VIII. | 2022 Spring |
1 |
| 2 |
34287985 | Synthesis of coagulation factors during long-term ex situ liver perfusion. | 2022 Feb |
1 |
| 3 |
34655821 | Supraprophylactic Anti-Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin. | 2022 Jan |
1 |
| 4 |
34725832 | Conventional versus restricted anti-Xa-guided heparin protocol in adult patients undergoing extracorporeal membrane oxygenation. | 2022 Jan |
1 |
| 5 |
34816442 | Reassessing the Pediatric Dosing Recommendations for Unfractionated Heparin Using Real-World Data: A Pharmacokinetic-Pharmacodynamic Modeling Approach. | 2022 Jun |
5 |
| 6 |
35200221 | Two Cases of Acute Direct Oral Anticoagulant Overdose Without Adverse Effect. | 2022 Mar 1 |
1 |
| 7 |
35456329 | Monitoring of Anticoagulant Activity of Dabigatran and Rivaroxaban in the Presence of Heparins. | 2022 Apr 16 |
1 |
| 8 |
35551912 | Heparin activation of protein Z-dependent protease inhibitor (ZPI) allosterically blocks protein Z activation through an extended heparin-binding site. | 2022 May 10 |
4 |
| 9 |
32833716 | Heparin Anti-Xa Activity, a Readily Available Unique Test to Quantify Apixaban, Rivaroxaban, Fondaparinux, and Danaparoid Levels. | 2021 Mar 1 |
3 |
| 10 |
32885997 | A Systemwide Approach for Navigating the Dilemma of Oral Factor Xa Inhibitor Interference With Unfractionated Heparin Anti-Factor Xa Concentrations. | 2021 May |
4 |
| 11 |
32888192 | Continuous intravenous infusion of enoxaparin controls thrombin formation more than standard subcutaneous administration in critically ill patients. A sub-study of the ENOKSI thromboprophylaxis RCT. | 2021 Jan |
1 |
| 12 |
32959678 | Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator. | 2021 May |
2 |
| 13 |
33026569 | Filter clotting with continuous renal replacement therapy in COVID-19. | 2021 May |
2 |
| 14 |
33128209 | The Influence of Haemostatic System Maturation on the Dose-Response Relationship of Unfractionated Heparin. | 2021 Apr |
1 |
| 15 |
33176060 | Skeletal muscle myosin and cardiac myosin attenuate heparin's antithrombin-dependent anticoagulant activity. | 2021 Feb |
3 |
| 16 |
33216354 | Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin. | 2021 Mar 15 |
1 |
| 17 |
33302210 | Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy. | 2021 Feb |
1 |
| 18 |
33512867 | Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children. | 2021 Oct 1 |
1 |
| 19 |
33588972 | Low-molecular-weight heparin administered by subcutaneous catheter is a safe and effective anti-coagulation regimen in selected inpatient infants and children with complex congenital heart disease. | 2021 Sep |
1 |
| 20 |
33860518 | Factor XI as a Target for New Anticoagulants. | 2021 Apr |
1 |
| 21 |
33925501 | Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease. | 2021 Apr 27 |
1 |
| 22 |
34205548 | Optimization of Heparin Monitoring with Anti-FXa Assays and the Impact of Dextran Sulfate for Measuring All Drug Activity. | 2021 Jun 21 |
1 |
| 23 |
34428806 | Prevention of Venous Thromboembolism in Microvascular Surgery Patients Using Weight-Based Unfractionated Heparin Infusions. | 2021 Aug 24 |
1 |
| 24 |
34604133 | Assessing Anticoagulation in Neonates With Congenital Diaphragmatic Hernia During Extracorporeal Membrane Oxygenation: Does Anti-Factor Xa or Thromboelastometry Provide Additional Benefit? | 2021 |
3 |
| 25 |
32187355 | FcRn augments induction of tissue factor activity by IgG-containing immune complexes. | 2020 Jun 4 |
1 |
| 26 |
32216028 | Anti-factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors. | 2020 Jul |
3 |
| 27 |
32422680 | Thr90Ser Mutation in Antithrombin is Associated with Recurrent Thrombosis in a Heterozygous Carrier. | 2020 Jul |
2 |
| 28 |
32433187 | Perils of Antithrombotic Transitions: Effect of Oral Factor Xa Inhibitors on the Heparin Antifactor Xa Assay. | 2020 Oct |
1 |
| 29 |
32441664 | Quality performance for indirect Xa inhibitor monitoring in patients using international external quality data. | 2020 Oct 25 |
1 |
| 30 |
32526007 | Design and Implementation of an Anti-Factor Xa Heparin Monitoring Protocol. | 2020 Jun 15 |
3 |
| 31 |
32677060 | The Relationship between the Initial Anti-factor Xa Measurement and the Duration of Direct Oral Anticoagulant Influence in Patients Transitioning to Heparin. | 2020 Sep |
4 |
| 32 |
33214783 | Evaluation of Heparin Anti-Factor Xa Levels Following Antithrombin Supplementation in Pediatric Patients Supported With Extracorporeal Membrane Oxygenation. | 2020 |
1 |
| 33 |
30813751 | Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin. | 2019 Aug |
1 |
| 34 |
30947118 | Biomimetic engineering endothelium-like coating on cardiovascular stent through heparin and nitric oxide-generating compound synergistic modification strategy. | 2019 Jul |
1 |
| 35 |
30961988 | Anti-Factor Xa-Based Monitoring of Unfractionated Heparin: Clinical Outcomes in a Pediatric Cohort. | 2019 Jun |
3 |
| 36 |
31243789 | Clinical outcomes with unfractionated heparin monitored by anti-factor Xa vs. activated partial Thromboplastin time. | 2019 Sep |
1 |
| 37 |
31251821 | Intraoperative Unfractionated Heparin Unresponsiveness during Endovascular Repair of a Ruptured Abdominal Aortic Aneurysm following Administration of Andexanet Alfa for the Reversal of Rivaroxaban. | 2019 Aug |
3 |
| 38 |
31472056 | A new mechanism of the protamine-dependent hypotension after cardiopulmonary bypass and the role of calcium. | 2019 Jul 31 |
1 |
| 39 |
31797980 | Heparin Forms Polymers with Cell-free DNA Which Elongate Under Shear in Flowing Blood. | 2019 Dec 4 |
1 |
| 40 |
31893201 | Inferior Vena Cava Agenesis and Deep Vein Thrombosis: A Pharmacological Alternative to Vitamin K Antagonists. | 2019 |
1 |
| 41 |
28862013 | Influence of Direct Oral Anticoagulants on Anti-Factor Xa Measurements Utilized for Monitoring Heparin. | 2018 Feb |
2 |
| 42 |
29173042 | Antithrombin conformational modulation by D-myo-inositol 3,4,5,6-tetrakisphosphate (TMI), a novel scaffold for the development of antithrombotic agents. | 2018 Nov |
1 |
| 43 |
29212374 | Performance of Anti-Factor Xa Versus Activated Partial Thromboplastin Time for Heparin Monitoring Using Multiple Nomograms. | 2018 Mar |
1 |
| 44 |
29999301 | Mass Spectrometry Reveals a Multifaceted Role of Glycosaminoglycan Chains in Factor Xa Inactivation by Antithrombin. | 2018 Aug 14 |
5 |
| 45 |
30118980 | Metabolic glycan labeling and chemoselective functionalization of native biomaterials. | 2018 Nov |
1 |
| 46 |
30259961 | International consensus statement on the peri-operative management of direct oral anticoagulants in cardiac surgery. | 2018 Dec |
1 |
| 47 |
27736032 | Anti-activated factor II assay for monitoring unfractionated heparin in children: results of the HEARTCAT study. | 2017 Jan |
1 |
| 48 |
27917715 | Antiplatelet Agents and Anticoagulants in Patients with Chronic Kidney Disease - from Pathophysiology to Clinical Practice. | 2017 |
1 |
| 49 |
28043992 | Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'. | 2017 Apr 1 |
1 |
| 50 |
28486148 | Adaptive release of heparin from anticoagulant hydrogels triggered by different blood coagulation factors. | 2017 Aug |
3 |